Eli Lilly expects to miss its recent revenue estimate for 2024 by about $400 million, according to a preliminary report.

The top three pharmacy benefit managers hiked the prices of dozens of 'specialty' generic drugs, some by more than 1000% of ...

Private investment firm Bridgewest is combing its Australia-based biologics CDMO BioCina and its sterile injectable ...

Nippon Shinyaku pays $110M upfront to Regenxbio for US/Asia rights to RGX-121 and RGX-111 gene therapies for ...

Daiichi Sankyo is spending $132.5 million to buy an antibody outright that it had already licensed from Glycotope.

IgA1 reduction in 4 hours, outperforming Vertex's povetacicept and Otsuka's sibeprenlimab. Plans for Phase 3 in IgAN.

IgA1 reduction in 4 hours, outperforming Vertex's povetacicept and Otsuka's sibeprenlimab. Plans for Phase 3 in IgAN.

XO Health launches health plan in 4 cities, offering employers alternative coverage with fixed-price care packages and ...

Four Lykos Therapeutics board members have stepped down and another departed last month, the aftermath of a stalemate over how to finance the psychedelic company's clinical future.

Anavex Life Sciences is back with more data for a pill that it’s looking to get approved in a variety of neurodegenerative ...

Is the frenzy of JPM dealmaking finally underway? GSK announced Monday morning that it will acquire the privately-held ...

The US Court of Appeals for the Federal Circuit on Friday found a key patent of Novartis' Entresto valid, reversing a lower ...